Effective Pharmacophore for CDC25 Phosphatases Enzyme Inhibitors: Newly Synthesized Bromothiazolopyrimidine Derivatives

Author(s): Mahmoud El-Shahat*, Mowafia. A.M. Salama, Ahmed F. El-Farargy, Mamdouh M. Ali, Dalia M. Ahmed

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 21 , Issue 1 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Thiazolopyrimidine analogues are versatile synthetic scaffold possessing wide spectrum of biological interests involving potential anticancer activity.

Objective: To report the synthesis of novel bromothiazolopyrimidine derivatives and the study of both molecular modeling and in-vitro anticancer activity.

Methods: Novel bromothiazolopyrimidine derivatives 5-18 have been prepared from 2-bromo-3-(4- chlorophenyl)-1-(3,4-dimethylphenyl)-propenone 3 as a key starting compound. The anti-cancer activities of the new compounds were evaluated against HepG2, MCF-7, A549 and HCT116 cell lines.

Results: The compounds 16, 17 and 18 showed cytotoxic and growth inhibitory activities on both colon and lung cells. The cytotoxic activities of the novel synthetic compounds 8, 9, 11, 16, 17 and 18 were due to CDC25 phosphatases inhibition as shown by the enzymatic binding assay. Although compounds 8, 9 and 11 have only demonstrated CDC25B phosphatases inhibition.

Conclusion: The novel bromothiazolopyrimidine derivatives showed promising in vitro anticancer activities against colon cancer HCT116 and lung cancer A549 cell lines comparable to the anticancer drug doxorubicin.

Keywords: Bromothiazolopyrimidines, molecular modeling, CDC25 phosphatases inhibitor, HepG2, MCF-7, A549, HCT116.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 19 June, 2020
Page: [118 - 131]
Pages: 14
DOI: 10.2174/1389557520666200619182519
Price: $65

Article Metrics

PDF: 17